Basel, Switzerland – Lonza’s integration of Capsugel is on track as the company forecasts combined high single-digit sales growth for the year. The first joint product offerings are in consumer health and sports nutrition.
“Lonza sustained strong performance and growth of the company in the first nine months of the year, which proves the rationale behind our strategic direction,” said Richard Ridinger, CEO of Lonza, in a statement. “Our focus now is on the successful integration of Capsugel in order to realize the expected synergies and further boost our ambition to become the leading integrated service provider for the pharma and healthcare industries. The first three months of the integration have been promising. We have confirmed the close cultural fit while we’ve been bringing the first combined business opportunities to life.”
After the July 5 closing of the Capsugel acquisition, the post-deal integration began immediately, the company reports. Business and functional integration is on track with key managers from both Lonza and Capsugel leading the integration activities.
Lonza and Capsugel employees are committed to the common path of offering high-quality products and services along the healthcare continuum – from ingredient sourcing to finished dosage form.
Ten new dietary supplement formulas have launched with Lonza’s ingredients, powered by Capsugel’s formulation and finished dosage forms know-how. They address sports, mood, sleep, healthy weight and immunity.
In Q3 2017 Capsugel performed in line with expectations with particularly strong results in Consumer Health and Nutrition. Lonza confirms its positive outlook for Capsugel to deliver the expected synergies and growth targets. Combined financial figures will be reported with the full-year results 2017 in January 2018.
Published on WholeFoods Magazine Online, 10/26/17